David Kingdon, MD, professor of mental health care delivery, University of Southampton, outlined some future avenues for research on the use of cognitive behavioral therapy (CBT) in psychosis, including the benefits of “worry periods” and studies on sleep.
David Kingdon, MD, professor of mental health care delivery, University of Southampton, outlined some future avenues for research on the use of cognitive behavioral therapy (CBT) in psychosis, including the benefits of “worry periods” and studies on sleep.
Transcript
What are some future directions for research on CBT in psychosis?
Well, there’s been some very interesting developments in terms of just treatments, so one study we’ve been involved with, with Dan Freeman at Oxford, is looking at worry in psychosis and paranoia. It’s obvious when you think about it that people who are paranoid are very worried about what’s happening to them. So using the sort of techniques that have been used with worry in anxiety, in generalized anxiety disorder, has been shown to be really effective. Helping people understand why you worry, how it could be helpful, but how it can also be negative. Beginning to develop some problem solving for it.
Also, and I think we were very surprised that patients really took to this, but having a worry period. So talking with patients about, you know, why worry all day? It doesn’t get you anywhere. Why not select a period during the day, half an hour or so, in which you’re going to do your worrying and then you’re going to leave it behind. And I have to say, we were very skeptical that this might help, but in fact patients have taken to it very well. A paper was published in the Lancet, 2015, and showed really quite significant effects not just on worry, but on quality of life and conviction in the beliefs. So it’s a simple 6-session intervention that’s helpful. There’s also work going on on sleep, because we know sleep exacerbates psychotic symptoms, and again psychological treatments can help with that.
And probably the most important is also on how we can see that these techniques are made most available. It does seem that some of them need continuing boosting. So we did a study on clozapine patients who had CBT, had persistent symptoms. What we found was a really good outcome at the end, but when the therapy stopped, the effect began to reduce. And just as if you’d stopped clozapine, you’d expect the effect to reduce, we also need to have ways of maintaining that, probably using community care workers, community nurses and others in that.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More